JP2021514820A - 脱細胞化骨細胞外マトリックスヒドロゲルで強化された脱細胞化骨生体材料 - Google Patents
脱細胞化骨細胞外マトリックスヒドロゲルで強化された脱細胞化骨生体材料 Download PDFInfo
- Publication number
- JP2021514820A JP2021514820A JP2020568008A JP2020568008A JP2021514820A JP 2021514820 A JP2021514820 A JP 2021514820A JP 2020568008 A JP2020568008 A JP 2020568008A JP 2020568008 A JP2020568008 A JP 2020568008A JP 2021514820 A JP2021514820 A JP 2021514820A
- Authority
- JP
- Japan
- Prior art keywords
- bone
- decellularized
- extracellular matrix
- biomaterial
- matrix hydrogel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000988 bone and bone Anatomy 0.000 title claims abstract description 108
- 239000012620 biological material Substances 0.000 title claims abstract description 60
- 210000002744 extracellular matrix Anatomy 0.000 title claims abstract description 41
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 title claims abstract description 40
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 title claims abstract description 40
- 239000000017 hydrogel Substances 0.000 title claims abstract description 27
- 230000007547 defect Effects 0.000 claims abstract description 15
- 238000011161 development Methods 0.000 claims abstract description 13
- 241001465754 Metazoa Species 0.000 claims abstract description 8
- 210000004027 cell Anatomy 0.000 claims abstract description 8
- -1 bioreactors Substances 0.000 claims abstract description 4
- 239000007943 implant Substances 0.000 claims abstract description 4
- 239000002114 nanocomposite Substances 0.000 claims abstract description 3
- 239000000463 material Substances 0.000 claims description 25
- 210000001519 tissue Anatomy 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 12
- 230000008569 process Effects 0.000 claims description 8
- 239000000499 gel Substances 0.000 claims description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 230000011164 ossification Effects 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000011248 coating agent Substances 0.000 claims description 2
- 238000000576 coating method Methods 0.000 claims description 2
- 238000012937 correction Methods 0.000 claims description 2
- 230000000399 orthopedic effect Effects 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 claims description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims 2
- 241000282412 Homo Species 0.000 claims 1
- 208000006735 Periostitis Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 230000003416 augmentation Effects 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- JCJGVEIHVMUYGF-UHFFFAOYSA-N diethyl(methyl)azanium;acetate Chemical compound CC([O-])=O.CC[NH+](C)CC JCJGVEIHVMUYGF-UHFFFAOYSA-N 0.000 claims 1
- 238000009826 distribution Methods 0.000 claims 1
- 210000004696 endometrium Anatomy 0.000 claims 1
- 230000002255 enzymatic effect Effects 0.000 claims 1
- 230000001605 fetal effect Effects 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 238000007710 freezing Methods 0.000 claims 1
- 230000008014 freezing Effects 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 238000000227 grinding Methods 0.000 claims 1
- 230000000366 juvenile effect Effects 0.000 claims 1
- 210000003460 periosteum Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000013223 septicemia Diseases 0.000 claims 1
- 238000002791 soaking Methods 0.000 claims 1
- 238000005728 strengthening Methods 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
- 230000018109 developmental process Effects 0.000 abstract description 12
- 238000011160 research Methods 0.000 abstract description 11
- 239000011159 matrix material Substances 0.000 abstract description 8
- 238000011282 treatment Methods 0.000 abstract description 8
- 230000035876 healing Effects 0.000 abstract description 6
- 210000000130 stem cell Anatomy 0.000 abstract description 5
- 239000000969 carrier Substances 0.000 abstract description 4
- 238000011049 filling Methods 0.000 abstract description 4
- 238000000338 in vitro Methods 0.000 abstract description 4
- 238000001727 in vivo Methods 0.000 abstract description 4
- 230000011712 cell development Effects 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 3
- 230000010354 integration Effects 0.000 abstract description 3
- 239000000021 stimulant Substances 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 2
- 230000002163 immunogen Effects 0.000 abstract description 2
- 238000010586 diagram Methods 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 239000000047 product Substances 0.000 description 22
- 239000003102 growth factor Substances 0.000 description 12
- 238000005516 engineering process Methods 0.000 description 9
- 230000010478 bone regeneration Effects 0.000 description 8
- 102000008186 Collagen Human genes 0.000 description 7
- 108010035532 Collagen Proteins 0.000 description 7
- 229920001436 collagen Polymers 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 229920001610 polycaprolactone Polymers 0.000 description 6
- 239000004632 polycaprolactone Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 5
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 5
- 239000011147 inorganic material Substances 0.000 description 5
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 5
- 230000017423 tissue regeneration Effects 0.000 description 5
- 229920000954 Polyglycolide Polymers 0.000 description 4
- 229940112869 bone morphogenetic protein Drugs 0.000 description 4
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 4
- 229910010272 inorganic material Inorganic materials 0.000 description 4
- 239000004633 polyglycolic acid Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000000735 allogeneic effect Effects 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000002805 bone matrix Anatomy 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 239000011368 organic material Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 229920001059 synthetic polymer Polymers 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000003929 acidic solution Substances 0.000 description 2
- 239000000316 bone substitute Substances 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 230000007012 clinical effect Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 229920005615 natural polymer Polymers 0.000 description 2
- 229920000620 organic polymer Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 1
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 1
- 235000014653 Carica parviflora Nutrition 0.000 description 1
- 241000243321 Cnidaria Species 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 101001039157 Homo sapiens Leucine-rich repeat-containing protein 25 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100040695 Leucine-rich repeat-containing protein 25 Human genes 0.000 description 1
- 210000004322 M2 macrophage Anatomy 0.000 description 1
- 229920001410 Microfiber Polymers 0.000 description 1
- 208000034530 PLAA-associated neurodevelopmental disease Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000005313 bioactive glass Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000005312 bioglass Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000006041 cell recruitment Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000515 collagen sponge Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000005541 medical transmission Effects 0.000 description 1
- 239000003658 microfiber Substances 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000002121 nanofiber Substances 0.000 description 1
- 230000003589 nefrotoxic effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000012358 sourcing Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A61L27/3691—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by physical conditions of the treatment, e.g. applying a compressive force to the composition, pressure cycles, ultrasonic/sonication or microwave treatment, lyophilisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3608—Bone, e.g. demineralised bone matrix [DBM], bone powder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3641—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the site of application in the body
- A61L27/3645—Connective tissue
- A61L27/365—Bones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A61L27/3687—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
- A61L27/48—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with macromolecular fillers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/18—Use of ingredients of undetermined constitution or reaction products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/40—Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dispersion Chemistry (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Materials Engineering (AREA)
- Composite Materials (AREA)
- Hematology (AREA)
- Surgery (AREA)
- Materials For Medical Uses (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Prostheses (AREA)
Abstract
Description
・自家移植のドナーのモービィディティが高く利用可能性が限られる。
・骨バンク材料の入手可能性と品質が低い。
・免疫原性拒絶の可能性ならびに凍結/凍結乾燥同種移植片および異種移植片による疾患の伝播の潜在的リスクがある。
・従来の治療法では不十分で臨床結果が悪い可能性がある。
・無機生体材料の臨床効果が比較的弱く骨誘導能が低い。
・一部の材料の機械的圧縮および脆弱性に対するサポート能力が低い。
・製品の調製技術とバッチ品質の標準化の欠如。
・成長因子の適切な品質と可用性を保証する製品の欠如。
・細胞を内包可能な技術による一体製品の欠如。
・複数の成長因子を含む複合製品の欠如。
・骨組織の特定起源の製品の安全性の欠如。
・骨組織の特定領域から生成された製品の安全性の欠如。
・特定の年齢の骨組織から生成された製品の安全性の欠如。
・脱細胞化骨マトリックスの製品の安全性の欠如。
・患者、損傷、または生物学的目的ごとにカスタマイズされた製品の欠如。
・試験された既存のバイオリアクタモデルの効率が低い。
・インビトロ研究を目的とした製品の欠如。
・特に成長因子と組み合わせた場合、ハイブリッド製品のコストが高い。
Claims (11)
- 脱細胞化骨細胞外マトリックスヒドロゲルで強化された脱細胞化骨生体材料であって、
浄化、選択、粉砕、浸漬、洗浄、乾燥、凍結乾燥、および凍結の複数の工程後、化学的および酵素的脱細胞化プロセスを行った、天然の動物またはヒトの成年、若年、新生児または胎児の骨から得られることを特徴とする、脱細胞化骨細胞外マトリックスヒドロゲルで強化された脱細胞化骨生体材料。 - 特定の年齢のドナーから収集された材料を用いた脱細胞化プロセスにより得られることを特徴とする、請求項1に記載の脱細胞化骨細胞外マトリックスヒドロゲルで強化された脱細胞化骨生体材料。
- 骨膜、骨内膜、成長領域、骨化の様々な領域、関節面、緻密骨、海綿骨、または骨髄管などの骨組織の特定の領域から収集された材料を用いた脱細胞化プロセスにより得られることを特徴とする、請求項1または2に記載の脱細胞化骨細胞外マトリックスヒドロゲルで強化された脱細胞化骨生体材料。
- 組織の細胞外マトリックスを保存するために、Triton、ドデシル硫酸ナトリウム(SDS)、酢酸アビエタミドメチルジエチルアンモニウムなどの界面活性剤を、単独でまたは組み合わせて、異なる濃度で用いた脱細胞化プロセスにより得られることを特徴とする、請求項1〜3のいずれか一項に記載の脱細胞化骨細胞外マトリックスヒドロゲルで強化された脱細胞化骨生体材料。
- ゲル化または乾燥した脱細胞化細胞外マトリックスヒドロゲルコーティングから得られることを特徴とする、請求項1〜4のいずれか一項に記載の脱細胞化骨細胞外マトリックスヒドロゲルで強化された脱細胞化骨生体材料。
- 粉末、様々な粒度分布の顆粒、ブロック、またはゲル形態で提供され骨移植片として使用される、請求項1〜5のいずれか一項に記載の脱細胞化骨細胞外マトリックスヒドロゲルで強化された脱細胞化骨生体材料。
- 動物および/またはヒトの歯科治療、抜歯、根切断、3壁性骨欠損、クレーター状骨欠損、深くて狭い半敗血症、歯根間欠損、または抽出、骨増強、もしくはインプラントの他の技術と組み合わせて使用される、請求項1〜6のいずれか一項に記載の脱細胞化骨細胞外マトリックスヒドロゲルで強化された脱細胞化骨生体材料。
- 動物および/またはヒトの整形外科手術、骨増強、骨折の矯正、および/または骨格の様々な領域の骨欠陥に使用される、請求項1〜7のいずれか一項に記載の脱細胞化骨細胞外マトリックスヒドロゲルで強化された脱細胞化骨生体材料。
- 示唆された適応症への使用に適したナノコンポジット、合成薬、および/または他の賦形剤と組み合わされる、請求項1〜8のいずれか一項に記載の脱細胞化骨細胞外マトリックスヒドロゲルで強化された脱細胞化骨生体材料。
- 間葉系幹細胞、前駆細胞、または成熟細胞の培養または系譜の開発および確立における組織工学用途のバイオリアクタまたはフレームワークとして使用される、請求項1〜9のいずれか一項に記載の脱細胞化骨細胞外マトリックスヒドロゲルで強化された脱細胞化骨生体材料。
- 3Dプリンタの材料として使用される、請求項1〜10のいずれか一項に記載の脱細胞化骨細胞外マトリックスヒドロゲルで強化された脱細胞化骨生体材料。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR1020180037269 | 2018-02-26 | ||
BR102018003726-9A BR102018003726B1 (pt) | 2018-02-26 | 2018-02-26 | Método de produção de um biomaterial ósseo, biomaterial ósseo e uso do mesmo |
PCT/BR2019/000008 WO2019161465A1 (pt) | 2018-02-26 | 2019-02-26 | Biomaterial de osso descelularizado enriquecido com hidrogel de matriz extracelular óssea descelularizada |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021514820A true JP2021514820A (ja) | 2021-06-17 |
JPWO2019161465A5 JPWO2019161465A5 (ja) | 2022-03-09 |
Family
ID=67686607
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020568008A Pending JP2021514820A (ja) | 2018-02-26 | 2019-02-26 | 脱細胞化骨細胞外マトリックスヒドロゲルで強化された脱細胞化骨生体材料 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20200405912A1 (ja) |
EP (1) | EP3760240A4 (ja) |
JP (1) | JP2021514820A (ja) |
KR (1) | KR20210005562A (ja) |
CN (1) | CN112203702A (ja) |
BR (1) | BR102018003726B1 (ja) |
CA (1) | CA3104006A1 (ja) |
IL (1) | IL276956A (ja) |
MX (1) | MX2020008912A (ja) |
WO (1) | WO2019161465A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114601971B (zh) * | 2022-01-24 | 2023-02-03 | 武汉理工大学 | 一种诱导骨再生的天然复合骨填充材料及其制备方法和用途 |
CN114712557A (zh) * | 2022-04-02 | 2022-07-08 | 中山大学附属口腔医院 | 一种水凝胶强化生物骨钙磷灰石支架及其制造方法 |
CN114870087A (zh) * | 2022-06-01 | 2022-08-09 | 万绵水 | 一种脱细胞支架及其制备方法 |
CN115429937B (zh) * | 2022-11-08 | 2023-04-28 | 圣至润合(北京)生物科技有限公司 | 一种软组织填充修复材料及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150010510A1 (en) * | 2013-07-03 | 2015-01-08 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Bone-Derived Extra Cellular Matrix Gel |
JP2015528340A (ja) * | 2012-09-04 | 2015-09-28 | ユニヴァーシティ オブ リーズUniversity Of Leeds | 複合骨移植片 |
WO2016032197A1 (ko) * | 2014-08-25 | 2016-03-03 | 주식회사 셀루메드 | 골형성단백질과 세포외기질이 코팅된 골 이식재 및 이의 제조방법 |
US20170021059A1 (en) * | 2015-05-22 | 2017-01-26 | Ilyas Inci | Process for bone tissue decellularization |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080233203A1 (en) * | 2007-03-21 | 2008-09-25 | Jennifer Woodell-May | Porous orthapedic materials coated with demineralized bone matrix |
CN106913907B (zh) * | 2015-12-25 | 2022-04-05 | 北京瑞健高科生物科技有限公司 | 一种具有结构记忆特性的细胞生长支架的制备方法 |
CN106075584B (zh) * | 2016-08-24 | 2019-07-05 | 天津市天津医院 | 可注射性软骨脱细胞外基质混合脱钙骨基质水凝胶及其制备方法 |
CN107349471A (zh) * | 2017-06-16 | 2017-11-17 | 卓阮医疗科技(苏州)有限公司 | 一种载药缓释的复合组织修复材料及其制备方法 |
-
2018
- 2018-02-26 BR BR102018003726-9A patent/BR102018003726B1/pt active IP Right Grant
-
2019
- 2019-02-26 JP JP2020568008A patent/JP2021514820A/ja active Pending
- 2019-02-26 CA CA3104006A patent/CA3104006A1/en active Pending
- 2019-02-26 KR KR1020207028016A patent/KR20210005562A/ko unknown
- 2019-02-26 MX MX2020008912A patent/MX2020008912A/es unknown
- 2019-02-26 US US16/976,052 patent/US20200405912A1/en not_active Abandoned
- 2019-02-26 CN CN201980028528.0A patent/CN112203702A/zh active Pending
- 2019-02-26 EP EP19756598.9A patent/EP3760240A4/en active Pending
- 2019-02-26 WO PCT/BR2019/000008 patent/WO2019161465A1/pt unknown
-
2020
- 2020-08-26 IL IL276956A patent/IL276956A/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015528340A (ja) * | 2012-09-04 | 2015-09-28 | ユニヴァーシティ オブ リーズUniversity Of Leeds | 複合骨移植片 |
US20150010510A1 (en) * | 2013-07-03 | 2015-01-08 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Bone-Derived Extra Cellular Matrix Gel |
WO2016032197A1 (ko) * | 2014-08-25 | 2016-03-03 | 주식회사 셀루메드 | 골형성단백질과 세포외기질이 코팅된 골 이식재 및 이의 제조방법 |
US20170021059A1 (en) * | 2015-05-22 | 2017-01-26 | Ilyas Inci | Process for bone tissue decellularization |
Non-Patent Citations (1)
Title |
---|
CHEN, G. ET AL: "Decellularized Bone Matrix Scaffold for Bone Regeneration", METHODS IN MOLECULAR BIOLOGY, JPN6022053974, 2017, ISSN: 0004953758 * |
Also Published As
Publication number | Publication date |
---|---|
KR20210005562A (ko) | 2021-01-14 |
CN112203702A (zh) | 2021-01-08 |
WO2019161465A1 (pt) | 2019-08-29 |
EP3760240A4 (en) | 2021-12-01 |
CA3104006A1 (en) | 2019-08-29 |
BR102018003726B1 (pt) | 2023-04-11 |
EP3760240A1 (en) | 2021-01-06 |
IL276956A (en) | 2020-10-29 |
BR102018003726A2 (pt) | 2019-09-10 |
MX2020008912A (es) | 2021-01-08 |
US20200405912A1 (en) | 2020-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Tahmasebi et al. | Current biocompatible materials in oral regeneration: a comprehensive overview of composite materials | |
Griffin et al. | Evolution of bone grafting: bone grafts and tissue engineering strategies for vascularized bone regeneration | |
Venkatesan et al. | Role of alginate in bone tissue engineering | |
Amini et al. | Bone tissue engineering: recent advances and challenges | |
EP2109444B1 (en) | Bone growth particles and osteoinductive composition thereof | |
Wickramasinghe et al. | A novel classification of bone graft materials | |
JP2021514820A (ja) | 脱細胞化骨細胞外マトリックスヒドロゲルで強化された脱細胞化骨生体材料 | |
Zhao et al. | Osteogenic media and rhBMP-2-induced differentiation of umbilical cord mesenchymal stem cells encapsulated in alginate microbeads and integrated in an injectable calcium phosphate-chitosan fibrous scaffold | |
Rahmati et al. | Biomaterials for regenerative medicine: Historical perspectives and current trends | |
Munhoz et al. | Use of collagen/chitosan sponges mineralized with hydroxyapatite for the repair of cranial defects in rats | |
Leng et al. | Material-based therapy for bone nonunion | |
Cho et al. | Natural sources and applications of demineralized bone matrix in the field of bone and cartilage tissue engineering | |
Gaihre et al. | Thermoresponsive injectable microparticle–gel composites with recombinant BMP-9 and VEGF enhance bone formation in rats | |
Gundu et al. | Recent developments of biomaterial scaffolds and regenerative approaches for craniomaxillofacial bone tissue engineering | |
Wu et al. | Eggshell microparticle reinforced scaffolds for regeneration of critical sized cranial defects | |
Motamedian et al. | Bone tissue engineering: a literature review | |
Zhang et al. | Advancing collagen-based biomaterials for oral and craniofacial tissue regeneration | |
Fattahian et al. | Biomaterials, substitutes, and tissue engineering in bone repair: current and future concepts | |
Chen et al. | Cranioplasty using osteoconductive scaffold and platelet glue | |
Zhang et al. | Immobilization of RGD peptide onto the surface of apatite-wollastonite ceramic for enhanced osteoblast adhesion and bone regeneration | |
Ursino et al. | Bone tissue engineering | |
Zhou et al. | Extracellular Matrix-based Materials for Bone Regeneration | |
US10183095B2 (en) | Treatment of skeletal voids with implantable substrate hydrated with bone marrow concentrate | |
en Odontología et al. | Bone substitutes used in dentistry | |
Sever et al. | Prefabrication of vascularized bone graft using an interconnected porous calcium hydroxyapatite ceramic in presence of vascular endothelial growth factor and bone marrow mesenchymal stem cells: experimental study in rats |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220228 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220228 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20221214 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221227 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230327 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230627 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230927 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20240206 |